137 related articles for article (PubMed ID: 1429045)
1. Autologous graft-versus-host disease: a novel approach for antitumor immunotherapy.
Hess AD; Jones RJ; Morris LE; Noga SJ; Vogelsang GB; Santos GW
Hum Immunol; 1992 Jul; 34(3):219-24. PubMed ID: 1429045
[TBL] [Abstract][Full Text] [Related]
2. Syngeneic/Autologous Graft-vs-Host Disease: Mobilization of Autoimmune Mechanisms as Antitumor Immunotherapy.
Hess AD
Cancer Control; 1994 May; 1(3):201-207. PubMed ID: 10886968
[TBL] [Abstract][Full Text] [Related]
3. Immunobiology and immunotherapeutic implications of syngeneic/autologous graft-versus-host disease.
Hess AD; Thoburn CJ
Immunol Rev; 1997 Jun; 157():111-23. PubMed ID: 9255625
[TBL] [Abstract][Full Text] [Related]
4. Autologous graft-vs-host disease: mechanisms and potential therapeutic effect.
Hess AD; Jones RC; Santos GW
Bone Marrow Transplant; 1993; 12 Suppl 3():S65-9. PubMed ID: 8124261
[TBL] [Abstract][Full Text] [Related]
5. Graft-versus-host disease after autologous bone marrow transplantation: a realistic expectation?
Niederwieser D; Eibl B; Nachbaur D
Wien Med Wochenschr; 1995; 145(2-3):25-7. PubMed ID: 7762248
[TBL] [Abstract][Full Text] [Related]
6. Synergism of interleukin-2 and cyclosporine A in induction of a graft-versus-tumor effect without graft-versus-host disease after syngeneic bone marrow transplantation.
Charak BS; Agah R; Mazumder A
Blood; 1992 Jul; 80(1):179-84. PubMed ID: 1611084
[TBL] [Abstract][Full Text] [Related]
7. Cytokine and chemokine profiles in autologous graft-versus-host disease (GVHD): interleukin 10 and interferon gamma may be critical mediators for the development of autologous GVHD.
Miura Y; Thoburn CJ; Bright EC; Chen W; Nakao S; Hess AD
Blood; 2002 Oct; 100(7):2650-8. PubMed ID: 12239181
[TBL] [Abstract][Full Text] [Related]
8. The effects of interleukin 10 and interferon gamma cytokine gene polymorphisms on survival after autologous bone marrow transplantation for patients with breast cancer.
Wu JM; Bensen-Kennedy D; Miura Y; Thoburn CJ; Armstrong D; Vogelsang GB; Hess AD
Biol Blood Marrow Transplant; 2005 Jun; 11(6):455-64. PubMed ID: 15931634
[TBL] [Abstract][Full Text] [Related]
9. Autologous graft-versus-host disease: a new frontier in immunotherapy.
Hess AD; Jones RJ; Morris LE; Noga SJ; Yeager AM; Vogelsang GB; Santos GW
Bone Marrow Transplant; 1992; 10 Suppl 1():16-21. PubMed ID: 1521086
[No Abstract] [Full Text] [Related]
10. Autologous graft-versus-host disease: immunotherapy of breast cancer after bone marrow transplantation.
Kennedy MJ; Jones RJ
Breast Cancer Res Treat; 1993; 26 Suppl():S31-40. PubMed ID: 8400331
[TBL] [Abstract][Full Text] [Related]
11. Specificity of effector T lymphocytes in autologous graft-versus-host disease: role of the major histocompatibility complex class II invariant chain peptide.
Hess AD; Bright EC; Thoburn C; Vogelsang GB; Jones RJ; Kennedy MJ
Blood; 1997 Mar; 89(6):2203-9. PubMed ID: 9058745
[TBL] [Abstract][Full Text] [Related]
12. Interferon-gamma potentiates the antitumor effect of cyclosporine-induced autoimmunity.
Noga SJ; Horwitz L; Kim H; Laulis MK; Hess AD
J Hematother; 1992; 1(1):75-84. PubMed ID: 1365019
[TBL] [Abstract][Full Text] [Related]
13. The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD?
Slavin S; Ackerstein A; Naparstek E; Or R; Weiss L
Bone Marrow Transplant; 1990 Sep; 6(3):155-61. PubMed ID: 2252954
[TBL] [Abstract][Full Text] [Related]
14. Immune modulation in autologous bone marrow transplantation: cyclosporine and gamma-interferon trial.
Vogelsang G; Bitton R; Piantadosi S; Altomonte V; Horn T; Jones R; Miller C; Marcellus D; Abrams R; Hess A
Bone Marrow Transplant; 1999 Sep; 24(6):637-40. PubMed ID: 10490729
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
16. The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement?
Har-Noy M; Slavin S
Med Hypotheses; 2008; 70(6):1186-92. PubMed ID: 18054441
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of syngeneic/autologous graft-versus-host disease.
Hess AD; Kennedy MJ; Ruvolo PP; Vogelsang GB; Jones RJ
Ann N Y Acad Sci; 1995 Dec; 770():189-202. PubMed ID: 8597360
[No Abstract] [Full Text] [Related]
18. Autoimmune diseases and autoimmunity post-bone marrow transplantation.
Sherer Y; Shoenfeld Y
Bone Marrow Transplant; 1998 Nov; 22(9):873-81. PubMed ID: 9827815
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer.
Kennedy MJ; Vogelsang GB; Jones RJ; Farmer ER; Hess AD; Altomonte V; Huelskamp AM; Davidson NE
J Clin Oncol; 1994 Feb; 12(2):249-57. PubMed ID: 8113833
[TBL] [Abstract][Full Text] [Related]
20. Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance.
Kline J; Subbiah S; Lazarus HM; van Besien K
Bone Marrow Transplant; 2008 Mar; 41(6):505-13. PubMed ID: 18026144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
